Multiplex neurodegeneration proteotoxicity platform reveals DNAJB6 promotes non-toxic FUS condensate gelation and inhibits neurotoxicity
简介:
- 作者: Samuel J Resnick, Seema Qamar, Pushya Krishna, Vladislav Korobeynikov, Hannes Ausserwoger, Alyssa Miller, Pietro Esposito, Juan A Varela, Jenny Sheng, Lei Haley Huang, Jonathon Nixon-Abell, Schuyler Melore, Chyi Wei Chung, Nino F Läubli, Sofia Kapsiani, Xuecong Li, Jingshu Wang, Nancy Zhang, Mahabub Maraj Alam, Alondra S Burguete, Theresa C Swayne, Yanyan Chen, Ya-Cheng Liao, Neil A Shneider, Michele Vendruscolo, Tuomas P J Knowles, Clemens F Kaminski, Francesco Simone Ruggeri, Gabriele S Kaminski Schierle, Peter St George-Hyslop, Alejandro Chavez
- 杂志: Nat Commun
- Doi: https://www.doi.org/10.1038/s41467-025-65178-0
- 出版日期: 2025/11/21
摘要
Neurodegenerative disorders (NDDs) are a family of diseases that remain poorly treated despite their growing global health burden. To gain insight into the mechanisms and modulators of neurodegeneration, we developed a yeast-based multiplex genetic screening platform. Using this platform, 32 NDD-associated proteins are probed against a library of 132 molecular chaperones from both yeast and humans, and an unbiased set of ~900 human proteins. We identify both broadly active and specific modifiers of our various cellular models. To illustrate the translatability of this platform, we extensively characterize a potent hit from our screens, the human chaperone DNAJB6. We show that DNAJB6 modifies the toxicity and solubility of multiple amyotrophic lateral sclerosis and frontotemporal dementia (ALS/FTD)-linked RNA-binding proteins (RBPs). Biophysical examination of DNAJB6 demonstrated that it co-phase separates with, and alters the behavior of FUS containing condensates by locking them into a loose gel-like state which prevents their fibrilization. Domain mapping and a deep mutational scan of DNAJB6 revealed key residues required for its activity and identified variants with enhanced activity. Finally, we show that overexpression of DNAJB6 prevents motor neuron loss and the associated microglia activation in a mouse model of FUS-ALS.
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。